Description

Velmupressin acetate (CAS No. 1647120-04-4) is a potent, selective, and short-acting peptidic agonist of the vasopressin V2 receptor (V2R). This compound is chemically described as c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2 and demonstrates remarkable receptor binding specificity. With EC50 values of 0.07 nM for human V2R (hV2R) and 0.02 nM for rat V2R (rV2R), Velmupressin acetate is among the most potent V2R-selective ligands available for research applications.

As a synthetic peptide derivative, Velmupressin acetate provides researchers with a valuable tool for exploring the molecular mechanisms of vasopressin receptor signaling. Its short-acting pharmacological profile makes it especially suitable for controlled receptor activation studies, minimizing long-term receptor desensitization effects.

Manufactured under GMP-compliant conditions, this compound achieves a purity of 99.47%, ensuring consistent performance across experimental applications. With its role as a selective agonist, Velmupressin acetate supports research into renal physiology, water reabsorption mechanisms, cardiovascular regulation, and pharmacological drug development.

This product is intended strictly for laboratory research use and is not approved for human or veterinary therapeutic use. Wholesale and retail supply options are available for universities, research institutes, biotech companies, and pharmaceutical laboratories.

Product Specifications

Mechanism of Action & Research Applications

Velmupressin acetate exerts its biological effects by selectively binding to the vasopressin V2 receptor (V2R), a G protein-coupled receptor predominantly expressed in the kidney. Upon activation, V2R stimulates adenylate cyclase, leading to increased intracellular cyclic AMP (cAMP) levels. Elevated cAMP enhances the trafficking and insertion of aquaporin-2 channels into the apical membrane of renal collecting duct cells, thereby promoting water reabsorption.

The exceptional selectivity of Velmupressin acetate enables researchers to study V2R signaling independently of other vasopressin receptor subtypes (V1a, V1b). Its short-acting nature allows for temporal control in experiments, providing a precise understanding of receptor-mediated effects.

Research Applications include:

• Investigation of vasopressin receptor pharmacology

• Modeling renal water balance and aquaporin regulation

• Exploring cardiovascular system regulation through vasopressin pathways

• Development of therapeutic candidates for conditions such as diabetes insipidus and hyponatremia

• Comparative studies of receptor selectivity between species (human vs. rat models)

Development & Formulation Notes

Velmupressin acetate is supplied as a highly pure lyophilized peptide powder, ensuring stability during transport and storage. The compound should be reconstituted in sterile water or buffer solution prior to use in experimental protocols. For long-term storage, aliquoting after reconstitution is recommended to avoid repeated freeze-thaw cycles.

As a GMP-certified product, Velmupressin acetate is produced under stringent quality control systems, providing researchers with confidence in batch-to-batch consistency, traceability, and reproducibility. Its short half-life in biological systems ensures reversible receptor activation, making it particularly valuable in time-dependent experimental designs.

This product is strictly intended for in vitro and in vivo laboratory studies and not for direct administration in humans or animals outside of controlled research environments.

Logistics, Packaging & Supply

Velmupressin acetate is packaged in sealed glass vials containing lyophilized powder, ensuring stability during transit. All shipments are handled under temperature-controlled conditions with insulated packaging and ice packs or dry ice when necessary.

• Standard packaging sizes: 1 mg, 5 mg, 10 mg vials (custom bulk orders available)

• Wholesale supply: Discounts available for research institutions and pharmaceutical companies

• Global shipping: Secure and traceable delivery options to ensure product integrity

Side Effects (For Reference Only in Models)

In experimental research settings, Velmupressin acetate may produce model-specific side effects, including:

• Temporary fluid retention

• Changes in electrolyte balance (e.g., sodium levels)

• Altered renal function in animal models

• Transient blood pressure variations

These effects highlight the importance of precise dosing and controlled study design in research applications.

Disclaimer

Velmupressin acetate is provided for laboratory research use only. It is not intended for human or veterinary use, clinical diagnosis, or therapeutic applications. Researchers should handle this compound in accordance with appropriate laboratory safety standards.

Keywords

Velmupressin acetate, Velmupressin CAS 1647120-04-4, V2 receptor agonist, GMP peptide supplier, selective vasopressin agonist, Velmupressin powder, Velmupressin peptide wholesale, receptor signaling research peptide, short-acting V2R agonist, Velmupressin acetate manufacturer